Toll Free: 1-888-928-9744

Systemic Mastocytosis - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 108 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Systemic Mastocytosis - Pipeline Review, H1 2016


Global Markets Direct's, 'Systemic Mastocytosis - Pipeline Review, H1 2016', provides an overview of the Systemic Mastocytosis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Systemic Mastocytosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the global therapeutic landscape of Systemic Mastocytosis
- The report reviews pipeline therapeutics for Systemic Mastocytosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Systemic Mastocytosis therapeutics and enlists all their major and minor projects
- The report assesses Systemic Mastocytosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Systemic Mastocytosis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Systemic Mastocytosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Systemic Mastocytosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Systemic Mastocytosis Overview 7 Therapeutics Development 8 Pipeline Products for Systemic Mastocytosis - Overview 8 Pipeline Products for Systemic Mastocytosis - Comparative Analysis 9 Systemic Mastocytosis - Therapeutics under Development by Companies 10 Systemic Mastocytosis - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Systemic Mastocytosis - Products under Development by Companies 14 Systemic Mastocytosis - Companies Involved in Therapeutics Development 15 AB Science SA 15 AbbVie Inc. 16 Allakos Inc. 17 Arog Pharmaceuticals, Inc. 18 Blueprint Medicines Corporation 19 Bristol-Myers Squibb Company 20 Deciphera Pharmaceuticals, LLC 21 Novartis AG 22 Patara Pharma, Inc. 23 Stemline Therapeutics, Inc. 24 Systemic Mastocytosis - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 AK-002 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 BLU-285 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 crenolanib besylate - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 cromolyn sodium - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 dasatinib - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 DCC-2618 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 ibrutinib - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 masitinib - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 midostaurin - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 SL-401 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Systemic Mastocytosis - Recent Pipeline Updates 61 Systemic Mastocytosis - Discontinued Products 98 Systemic Mastocytosis - Product Development Milestones 99 Featured News & Press Releases 99 May 02, 2016: AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis 99 Feb 01, 2016: AB Science announces that Rapporteurs appointed by the EMA have recommended to file a marketing authorization application for full approval for masitinib in severe systemic mastocytosis 99 Dec 07, 2015: AB Science announces results from Phase 3 randomized placebo-controlled trial of masitinib in adults with severe systemic mastocytosis unresponsive to optimal symptomatic treatment 102 Nov 30, 2015: AB Science Announces Positive Top-Line Results from Phase 3 Trial of Masitinib in Adults with Severe Systemic Mastocytosis 104 Sep 10, 2015: Blueprint Medicines Receives FDA Authorization to Advance Novel Drug Candidate into Clinical Trial for Systemic Mastocytosis 105 Dec 08, 2014: Blueprint Medicines Debuts Comprehensive Preclinical Data Set on First Selective Drug for Patients with Systemic Mastocytosis at 2014 American Society of Hematology Annual Meeting 106 Appendix 107 Methodology 107 Coverage 107 Secondary Research 107 Primary Research 107 Expert Panel Validation 107 Contact Us 107 Disclaimer 108
List of Tables
Number of Products under Development for Systemic Mastocytosis, H1 2016 8 Number of Products under Development for Systemic Mastocytosis - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Systemic Mastocytosis - Pipeline by AB Science SA, H1 2016 15 Systemic Mastocytosis - Pipeline by AbbVie Inc., H1 2016 16 Systemic Mastocytosis - Pipeline by Allakos Inc., H1 2016 17 Systemic Mastocytosis - Pipeline by Arog Pharmaceuticals, Inc., H1 2016 18 Systemic Mastocytosis - Pipeline by Blueprint Medicines Corporation, H1 2016 19 Systemic Mastocytosis - Pipeline by Bristol-Myers Squibb Company, H1 2016 20 Systemic Mastocytosis - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016 21 Systemic Mastocytosis - Pipeline by Novartis AG, H1 2016 22 Systemic Mastocytosis - Pipeline by Patara Pharma, Inc., H1 2016 23 Systemic Mastocytosis - Pipeline by Stemline Therapeutics, Inc., H1 2016 24 Assessment by Monotherapy Products, H1 2016 25 Number of Products by Stage and Target, H1 2016 27 Number of Products by Stage and Mechanism of Action, H1 2016 29 Number of Products by Stage and Route of Administration, H1 2016 31 Number of Products by Stage and Molecule Type, H1 2016 33 Systemic Mastocytosis Therapeutics - Recent Pipeline Updates, H1 2016 61 Systemic Mastocytosis - Discontinued Products, H1 2016 98

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.